The study’s measurements yielded an impressive tumor-to-background ratio and did not exhibit specific binding in the HER2-negative model, indicating the nanobody’s potential as both a radioimmunotherapy and imaging agent for HER2-positive breast cancers [55]. Here, ERBB2 is linked to breast carcinoma.